This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Blackfan-Diamond syndrome블랙판-다이아몬드증후군

ICD-10: D61.0 | Synonyms: Diamond-Blackfan anemia (DBA), Congenital pure red cell aplasia, Congenital hypoplastic anaemia, Erythrogenesis imperfecta

Contents
  1. History
  2. Causes
  3. Genetics
  4. General epidemiology
  5. Pathophysiology
  6. Symptoms
  7. Signs
  8. Screening
  9. Diagnosis
  10. Treatment
  11. Prognosis
  12. Prevention
  13. References

1. History

First description by Diamond and Blackfan

In 1938, American pediatricians Louis K. Diamond (1902~1999) and Kenneth D. Blackfan (1883~1941) at Boston Children's Hospital reported 4 cases of chronic severe anemia arising in infancy in which bone marrow examination showed selective deficiency of only erythroid precursors, with other blood cell lineages normal. They named the disease 'congenital hypoplastic anemia,' and this was the first systematic description. Subsequently, the concept of a lineage-specific congenital pure red cell aplasia was established.

Expansion of the clinical description

In 1961, Diamond and colleagues reported more than 30 additional cases and described in detail the clinical diversity of the disease, including response to steroid treatment, the possibility of spontaneous remission in some, and association with various congenital anomalies. Thereafter, the disease came to be called 'Diamond-Blackfan anemia' or 'Blackfan-Diamond syndrome' after its principal describers.

Discovery of ribosomal protein gene variants

In 1999, Draptchinskaia et al. found heterozygous variants in the RPS19 (ribosomal protein S19) gene in about 25% of DBA patients. This was highly significant as the first link between abnormal ribosome biogenesis and human genetic disease. Subsequently, in the 2000s, many ribosomal protein genes, including RPL5, RPL11, RPL35A, RPS24, and RPS17, were discovered as additional causative genes of DBA.

2. Causes

Haploinsufficiency of ribosomal protein genes

The main cause of DBA is heterozygous loss-of-function variants (haploinsufficiency) in ribosomal protein genes that make up the ribosomal subunits (40S or 60S). Causative ribosomal protein gene variants are identified in about 65~70% of all DBA patients. The most common genes include RPS19 (about 25%), RPL5 (about 7%), RPL11 (about 5%), RPL35A (about 4%), RPS24 (about 2%), RPS17 (about 1%), and RPS26 (about 6%).

GATA1 and other genes

In addition to RPS and RPL genes, variants in TSR2 (RPS26 maturation), GATA1 (heterozygous splice site variants, in some boys), and the EPO receptor gene (EPOR) have been reported to cause the DBA phenotype.

High proportion of de novo variants

About 40~45% of DBA is caused by de novo variants (new variants not present in the parents), and the remainder are familial forms with autosomal dominant inheritance. Even in familial forms, expressivity varies, and some carriers have only mild anemia or almost no symptoms.

3. Genetics

Autosomal dominant inheritance

DBA mostly follows autosomal dominant inheritance. A heterozygous variant alone causes an imbalance in ribosome biogenesis due to haploinsufficiency, resulting in disease. When inherited from a parent, the positive parent may also show an incomplete phenotype, such as mild anemia, red cell macrocytosis, and increased adenosine deaminase (ADA) activity.

Genotype-phenotype correlation

Congenital anomalies such as cleft palate, cardiac malformations, and thumb abnormalities are observed more frequently in patients with RPL5 and RPL11 variants. RPS19 variants are reported to tend toward a relatively mild phenotype and good steroid response, but individual variation is large.

Classification as a ribosomopathy

DBA, together with Shwachman-Diamond syndrome, cartilage-hair hypoplasia (CHH), and others, is classified in the group of 'ribosomopathies' caused by abnormal ribosome biogenesis. This concept has contributed to understanding that the ribosome biogenesis pathway plays a key role in human development, blood cell differentiation, and carcinogenesis.

4. General epidemiology

Worldwide incidence

The estimated incidence of DBA is about 5~7 per million births (up to 10 in some studies). It is evenly distributed worldwide and not concentrated in any particular ethnicity or region. The male-to-female ratio is nearly equal. The number of patients currently enrolled in the international Diamond Blackfan Anemia Registry (DBAR) reaches several thousand.

Status in Korea

In Korea, DBA is listed on the national rare disease list, and care is provided at specialized pediatric hematology-oncology centers. Small cohort studies on the incidence and the gene variant spectrum in Korea have been reported. Special Copayment Reduction is available in Korea.

Age at onset

DBA characteristically has onset in infancy. About 90% of patients are diagnosed within the first year of life, with a median age at diagnosis of 2~3 months. Occasionally, mild forms with diagnosis delayed until adulthood are also reported.

5. Pathophysiology

Ribosomal stress and p53 activation

Haploinsufficiency of ribosomal protein genes causes an imbalance of the 40S or 60S ribosomal subunits. Excess free ribosomal proteins (especially RPL5 and RPL11) bind directly to MDM2 (an E3 ubiquitin ligase), a negative regulator of p53, and inhibit MDM2-mediated degradation of p53. As a result, the p53 protein is stabilized and activated, increasing cell cycle G1 arrest and apoptosis.

Selective vulnerability of erythroid progenitors

p53 activation occurs in all cells, but erythroid progenitors (CFU-E and their precursors) have a higher ribosome demand than other cells and are more sensitive to p53-mediated cell death. In addition, the translation efficiency of GATA1, a transcription factor essential for erythroid progenitor differentiation, is particularly reduced in the setting of ribosomal protein deficiency, selectively blocking erythroid differentiation.

Reduced GATA1 translation efficiency

Abnormal ribosome biogenesis disproportionately reduces the translation of specific mRNAs (especially GATA1 mRNA). Reduced GATA1 protein suppresses expression of anti-apoptotic genes (such as BCL-XL) essential for the survival and differentiation of erythroid progenitors, accelerating erythroblast death.

6. Symptoms

Symptoms of severe anemia

The most central symptom of DBA is severe normochromic macrocytic anemia appearing early after birth (from several weeks to months of age). Pallor, poor feeding, growth failure, fatigue, palpitations, and tachycardia are the main symptoms. Because white blood cells and platelets are normal, there are no bleeding or infection symptoms.

Congenital anomalies

Congenital anomalies are present in about 30~47% of all DBA patients. Head and neck abnormalities (microcephaly, facial anomalies, cleft palate) are the most common, and thumb anomalies (triphalangeal thumb, duplicated thumb) are observed in about 15~20%. Cardiac malformations (such as ventricular septal defect), urinary tract anomalies, and facial anomalies (Robin sequence, flat nose, etc.) are also reported. Short stature is common.

Risk of secondary tumors

Patients with DBA have an increased risk of secondary malignancies. Myelodysplastic syndrome (MDS), acute myeloid leukemia (AML), osteosarcoma, and female genital cancers have been reported. The cumulative tumor incidence by age 30 is reported as about 20% in DBA registry data, which is markedly higher than in the general population.

7. Signs

Physical examination findings

In infants, severe pallor, tachycardia, heart murmur (anemic functional murmur), and growth delay are the main signs. Congenital anomalies (thumb abnormalities, cleft palate, cardiac malformations, facial anomalies) may be present. Splenomegaly is absent or mild (because the pathogenesis is a pure reduction in production rather than red cell production), and jaundice is also absent or mild.

Laboratory findings

The complete blood count characteristically shows normochromic macrocytic anemia (very low Hb, increased MCV), with normal white blood cells and platelets. Reticulocytes are markedly reduced or absent. Serum ADA (erythrocyte adenosine deaminase) activity is increased in 70~80% of DBA patients, which is useful for screening and for following atypical cases. Increased HbF (30~100%) is characteristic. Serum EPO is markedly elevated relative to the anemia.

Bone marrow findings

Bone marrow aspiration and biopsy show markedly reduced or absent erythroid precursors (erythroblasts) (<5%), while myeloid and megakaryocytic lineage cells are maintained normally. Abnormal erythroblast morphology (such as nuclear irregularity) may be observed.

8. Screening

Clinical clues for suspicion

DBA is suspected and further testing performed when the following findings are present in an infant: ① severe normochromic macrocytic anemia arising within the first year of life, ② reticulocytopenia, ③ normal white blood cells and platelets, ④ possible associated congenital anomalies (thumb abnormalities, cleft palate, cardiac malformations).

Measurement of erythrocyte ADA activity

Increased serum erythrocyte ADA activity is a useful screening test for the diagnosis of DBA. Increased ADA is observed in 70~80% of all DBA patients and has high specificity. However, normal ADA activity does not exclude DBA.

Family screening

Family screening of the parents and siblings of DBA patients for macrocytic anemia and increased ADA is recommended. Identifying carriers of the causative gene variant in the family is used for genetic counseling and for identifying transplant donors.

9. Diagnosis

Diagnostic criteria (International DBA Consortium)

Major criteria: ① age <1 year (or rarely later), ② normochromic macrocytic anemia, ③ reticulocytopenia, ④ selective reduction of only erythroid precursors in the bone marrow with normal cellularity. Supporting criteria: ⑤ ribosomal protein gene variant, ⑥ increased erythrocyte ADA activity, ⑦ congenital anomalies (characteristic of DBA), ⑧ family history (autosomal dominant), ⑨ response to steroid treatment.

Molecular genetic confirmation

NGS-based DBA gene panel testing (20 or more genes, including RPS19, RPL5, RPL11, RPL35A, RPS24, RPS17, and RPS26) is the standard for identifying the cause. The approximately 30~35% of patients in whom no gene variant is identified are diagnosed by clinical criteria. Cases due to large deletions/duplications are confirmed by MLPA or chromosomal microarray.

Differential diagnosis

Differentiation is needed from transient erythroblastopenia of childhood (TEC), acquired PRCA, Pearson syndrome, Fanconi anemia with selective erythroid involvement, Parvovirus B19 infection, and others. TEC usually occurs after 1 year of age and recovers spontaneously within weeks to months, and is distinguished from DBA by normal ADA activity and the absence of gene variants.

10. Treatment

Corticosteroid treatment

Steroid treatment is the first-line treatment of DBA. Prednisolone (2mg/kg/day) is used, with a response rate of about 70~80%. When there is a response, tapering to the minimum effective dose is attempted. Steroid adverse effects (Cushing syndrome, growth suppression, osteoporosis, susceptibility to infection) are a problem, and steroid dependence or refractoriness is common, especially in children. In infants under 1 year of age, transfusion is recommended first because of concerns about steroid adverse effects.

Chronic transfusion therapy

In steroid-refractory or steroid-dependent cases, Hb ≥8~9 g/dL is maintained with regular packed red blood cell transfusions. Iron overload from chronic transfusion is treated with deferasirox or deferoxamine. Regular monitoring of iron overload (serum ferritin, liver MRI T2*) is essential.

Hematopoietic stem cell transplantation and new treatments

Allogeneic hematopoietic stem cell transplantation is the curative treatment for steroid-refractory or steroid-dependent DBA. Long-term survival after transplantation from an HLA-matched sibling donor reaches about 85~90%. Permanent or temporary spontaneous remission occurs in about 20~25% of all DBA patients, with Hb maintained without treatment. Leucine supplementation, ACE-536/luspatercept, and others are under clinical investigation as new treatment candidates.

11. Prognosis

Prognosis of the steroid-responsive group

The prognosis of patients who respond to steroids is relatively good, and a normal quality of life is possible when the minimum effective dose is maintained or remission is achieved. In patients with long-term steroid dependence, steroid adverse effects (diabetes, osteoporosis, cataracts, growth delay, infections) affect the prognosis.

Prognosis of the transfusion-dependent group

In patients requiring chronic transfusion, iron overload leads to major organ complications (cardiac dysfunction, liver fibrosis, endocrine abnormalities). Diligent iron chelation therapy can reduce complications and prolong survival.

Secondary tumors and long-term survival

According to DBA registry data, the cumulative incidence of secondary malignancies such as MDS/AML, osteosarcoma, and genital cancers in DBA patients is 5~6 times higher than in the general population. The risk of solid tumors persists even after transplantation. The proportion of patients surviving into adulthood with appropriate treatment and management is increasing.

12. Prevention

Genetic counseling and prenatal diagnosis

Autosomal dominant inheritance (50% transmission risk with each pregnancy) is explained to the parents of DBA patients, and prenatal genetic testing (CVS or amniocentesis) or preimplantation genetic testing (PGT-M) is offered. In the case of a de novo variant, counseling covers that the recurrence risk in the next pregnancy is low but there is a risk of transmission (50%) to the child.

Prevention and surveillance of secondary tumors

For surveillance of MDS/AML and solid tumors in DBA patients, regular bone marrow examination (every 3~5 years or with clinical change), blood tests, and gynecologic examinations from adulthood (in women) are performed. Radiation exposure is minimized and smoking and drinking are avoided.

Prevention of iron overload

In patients on chronic transfusion, iron chelation therapy is started when serum ferritin exceeds 1,000 ng/mL. The degree of organ iron deposition is monitored by regular liver MRI T2* and cardiac MRI T2* to prevent complications.

13. References

  1. Diamond LK, Blackfan KD. Hypoplastic anemia. Am J Dis Child. 1938;56(3):464-467.
  2. Draptchinskaia N, Gustavsson P, Andersson B, et al. The gene encoding ribosomal protein S19 is mutated in Diamond-Blackfan anaemia. Nat Genet. 1999;21(2):169-175.
  3. Vlachos A, Ball S, Dahl N, et al. Diagnosing and treating Diamond Blackfan anaemia: results of an international clinical consensus conference. Br J Haematol. 2008;142(6):859-876.
  4. Lipton JM, Ellis SR. Diamond-Blackfan anemia: diagnosis, treatment, and molecular pathogenesis. Hematol Oncol Clin North Am. 2009;23(2):261-282.
  5. Farrar JE, Dahl N. Untangling the phenotypic heterogeneity of Diamond Blackfan anemia. Semin Hematol. 2011;48(2):124-135.
  6. Ludwig LS, Gazda HT, Eng JC, et al. Altered translation of GATA1 in Diamond-Blackfan anemia. Nat Med. 2014;20(7):748-753.
  7. Vlachos A, Rosenberger TA, Atsidaftos E, et al. Incidence of neoplasia in Diamond Blackfan anemia: a report from the Diamond Blackfan Anemia Registry. Blood. 2012;119(16):3815-3819.
  8. Orfali KA, Ohene-Abuakwa Y, Ball SE. Diamond Blackfan anaemia in the UK: clinical and genetic heterogeneity. Br J Haematol. 2004;125(2):243-252.
  9. Cmejla R, Cmejlova J, Handrkova H, et al. Ribosomal protein S17 gene (RPS17) is mutated in Diamond-Blackfan anemia. Hum Mutat. 2007;28(12):1178-1182.
  10. Da Costa L, Leblanc T, Mohandas N. Diamond-Blackfan anemia. Blood. 2020;136(11):1262-1273.
  11. Lee KH, Park HS. Clinical characteristics and treatment experience of patients with Diamond-Blackfan anemia in Korea. Clin Pediatr Hematol Oncol. 2017;24(1):22-30.
  12. Vlachos A, Muir E. How I treat Diamond-Blackfan anemia. Blood. 2010;116(19):3715-3723.